AU2008313622A1 - Solid dispersion product of N-aryl urea-based drugs - Google Patents

Solid dispersion product of N-aryl urea-based drugs Download PDF

Info

Publication number
AU2008313622A1
AU2008313622A1 AU2008313622A AU2008313622A AU2008313622A1 AU 2008313622 A1 AU2008313622 A1 AU 2008313622A1 AU 2008313622 A AU2008313622 A AU 2008313622A AU 2008313622 A AU2008313622 A AU 2008313622A AU 2008313622 A1 AU2008313622 A1 AU 2008313622A1
Authority
AU
Australia
Prior art keywords
group
phenyl
amino
alkyl
urea
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2008313622A
Other languages
English (en)
Inventor
Tanja Heitermann
Rudolf Schroeder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
Original Assignee
Abbott GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott GmbH and Co KG filed Critical Abbott GmbH and Co KG
Publication of AU2008313622A1 publication Critical patent/AU2008313622A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2008313622A 2007-10-19 2008-10-17 Solid dispersion product of N-aryl urea-based drugs Abandoned AU2008313622A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99961807P 2007-10-19 2007-10-19
US60/999,618 2007-10-19
PCT/EP2008/064076 WO2009050291A2 (fr) 2007-10-19 2008-10-17 Produit de dispersion solide de médicaments de type n-aryle à base d'urée

Publications (1)

Publication Number Publication Date
AU2008313622A1 true AU2008313622A1 (en) 2009-04-23

Family

ID=40089463

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008313622A Abandoned AU2008313622A1 (en) 2007-10-19 2008-10-17 Solid dispersion product of N-aryl urea-based drugs

Country Status (18)

Country Link
EP (1) EP2197425A2 (fr)
JP (1) JP2011500649A (fr)
KR (1) KR20100087170A (fr)
CN (1) CN101827584A (fr)
AU (1) AU2008313622A1 (fr)
BR (1) BRPI0818340A2 (fr)
CA (1) CA2699301A1 (fr)
CO (1) CO6270206A2 (fr)
CR (1) CR11442A (fr)
DO (1) DOP2010000117A (fr)
EC (1) ECSP10010183A (fr)
GT (1) GT201000102A (fr)
MX (1) MX2010004291A (fr)
PA (1) PA8800101A1 (fr)
RU (1) RU2010119929A (fr)
UA (1) UA100865C2 (fr)
WO (1) WO2009050291A2 (fr)
ZA (1) ZA201002095B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009100176A2 (fr) * 2008-02-07 2009-08-13 Abbott Laboratories Forme pharmaceutique pour administration orale d’un inhibiteur de tyrosine kinase
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
MX2012014387A (es) * 2010-06-09 2013-05-01 Abbvie Inc Dispersiones solidas que contienen inhibidores de cinasa.
CA2855243C (fr) 2011-11-11 2020-04-14 Novartis Ag Procede de traitement d'une maladie proliferative
LT2782557T (lt) * 2011-11-23 2018-12-27 Array Biopharma, Inc. Farmacinės kompozicijos
WO2014003677A1 (fr) * 2012-06-28 2014-01-03 Xspray Microparticles Ab Compositions pharmaceutiques comprenant des particules de dispersion solide contenant du tadalafil
WO2014003678A1 (fr) * 2012-06-28 2014-01-03 Xspray Microparticles Ab Compositions pharmaceutiques comprenant de l'ambrisentan et des particules de dispersion solide contenant du tadalafil

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070104780A1 (en) * 2005-10-25 2007-05-10 Lipari John M Formulation comprising a drug of low water solubility and method of use thereof
WO2007066189A2 (fr) * 2005-12-09 2007-06-14 Pfizer Products Inc. Sels, promedicaments et formulations de 1-[5-(4-amino-7-isopropyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-uree
EP2089003A1 (fr) * 2006-11-09 2009-08-19 Abbott GmbH & Co. KG Forme de dosage pharmaceutique pour l'administration orale d'un inhibiteur de la tyrosine kinase

Also Published As

Publication number Publication date
DOP2010000117A (es) 2010-05-15
WO2009050291A2 (fr) 2009-04-23
BRPI0818340A2 (pt) 2015-04-22
UA100865C2 (ru) 2013-02-11
ZA201002095B (en) 2011-11-30
CA2699301A1 (fr) 2009-04-23
PA8800101A1 (es) 2009-05-15
JP2011500649A (ja) 2011-01-06
EP2197425A2 (fr) 2010-06-23
CO6270206A2 (es) 2011-04-20
CR11442A (es) 2010-09-06
CN101827584A (zh) 2010-09-08
WO2009050291A3 (fr) 2010-04-08
RU2010119929A (ru) 2011-11-27
KR20100087170A (ko) 2010-08-03
MX2010004291A (es) 2010-08-02
GT201000102A (es) 2012-03-12
ECSP10010183A (es) 2010-06-29

Similar Documents

Publication Publication Date Title
KR102265644B1 (ko) 글루코키나아제 활성화제의 경구제제 및 이의 제조방법
AU2008313622A1 (en) Solid dispersion product of N-aryl urea-based drugs
US20090143423A1 (en) Solid dispersion product containing n-aryl urea-based compound
BR112020024107A2 (pt) combinação farmacêutica, composição, e preparação de combinação que compreende ativador de glucoquinase e inibidor de sglt-2 e métodos de preparação e uso dos mesmos
US10493161B2 (en) Solution for spray drying comprising hypromellose acetate succinate and method for producing solid dispersion
BRPI0715712B1 (pt) Composição farmacêutica adequada para a administração oral compreendendo um derivado de triazol[4,5d]pirimidina
KR20120109522A (ko) 시그마 수용체 리간드들을 포함하는 약학 조성물들
JP2003503380A (ja) 無定形硝酸エステルおよびその製剤組成物
WO2002040054A1 (fr) Preparation pharmaceutique contenant de la copolyvidone
TW202216117A (zh) 經口用醫藥組成物及其製造方法
JP2001511796A (ja) 環状四級アンモニウム化合物を経口投与するための乾燥形態の薬学的調合剤
JP2003527424A (ja) オキサゾリジノン錠剤製剤
CN107072954B (zh) 用于口服给药的包含洛贝格列酮的药物组合物
KR100912196B1 (ko) Ｌｔｂ4 길항제를 함유하는 약제학적 제형
WO2020122244A1 (fr) Comprimé, et procédé de fabrication de celui-ci
JP2002212063A (ja) コポリビドン含有製剤
EP4076407B1 (fr) Composition pharmaceutique d'un composé pyrazole dispersé dans une matrice polymère
US20240216347A1 (en) Bezuclastinib formulations
WO2021006267A1 (fr) Sel de dérivé de pyrazole et préparation de dérivé de pyrazole
JP2024091760A (ja) 非晶質固体分散体を含む複合物
JP5106119B2 (ja) シクロオキシゲナーゼ−２阻害剤を含む経口投与用の薬剤、およびその調製方法
CA3232832A1 (fr) Composition pharmaceutique et son procede de preparation
RU2261095C1 (ru) Лекарственная форма, обладающая нестероидным противовоспалительным действием, и способ ее изготовления
CN106456612A (zh) 经口给药用医药组合物
JPWO2020246526A1 (ja) キサンチンオキシダーゼ阻害剤含有腸溶性製剤

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application